文献速递浆细胞疾病

维奈克拉联合地塞米松治疗复发难治性t(11;14)多发性骨髓瘤

Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
PubMed 文献 · Am J Hematol · 2021-01-19

本研究评估维奈克拉联合地塞米松(VenDex)在t(11;14)阳性复发难治多发性骨髓瘤中的安全性和疗效。开放标签多中心研究分两阶段,P1组20例、P2组31例,中位既往治疗线数3/5线,ORR分别为60%/48%。VenDex在重度经治患者中显示疗效且安全性可控。

要点

  • VenDex在t(11;14)阳性RRMM中ORR达60%/48%。
  • 主要3/4级血液学不良事件为淋巴细胞减少、中性粒细胞减少、血小板减少和贫血。
  • 缓解与del(17p)、gain(1q)及MAPK/NF-kB通路突变无关。

核心结论

  • VenDex在重度经治的t(11;14)阳性复发难治多发性骨髓瘤患者中显示出疗效和可控的安全性。

研究设计与样本

  • 开放标签、多中心研究,分P1和P2两阶段;P1组20例、P2组31例t(11;14)阳性复发难治多发性骨髓瘤患者接受VenDex治疗。

主要发现

  • P1/P2患者中位既往治疗线数分别为3线和5线,对达雷妥尤单抗难治比例分别为20%和87%。
  • P1/P2的ORR分别为60%和48%,12个月缓解持续时间估计分别为50%和61%,中位至进展时间分别为12.4个月和10.8个月。
  • ≥10%发生的3/4级血液学不良事件:P1/P2淋巴细胞减少20%/19%、中性粒细胞减少15%/7%、血小板减少10%/10%、贫血5%/16%。
  • 在可评估生物标志物的患者中,缓解与合并del(17p)或gain(1q)以及MAPK、NF-kB等关键致癌信号通路突变无关。

关键数值与推荐

  • VenDex方案:口服维奈克拉800 mg/天,口服地塞米松40 mg(≥75岁患者20 mg),每21天周期的第1、8、15天给药。
  • P1主要目标为安全性和药代动力学;P2进一步评估疗效,包括客观缓解率和≥非常好的部分缓解。

临床怎么用

  • 对于t(11;14)阳性复发难治多发性骨髓瘤,尤其是重度经治患者,可考虑VenDex方案。
  • 治疗期间需监测淋巴细胞减少、中性粒细胞减少、血小板减少和贫血等血液学不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax (Ven) is a selective small-molecule inhibitor of BCL-2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated the safety and efficacy of Ven and dexamethasone (VenDex) combination in patients with t(11;14) positive relapsed/refractory (R/R) multiple myeloma (MM). This open-label, multicenter study had two distinct phases (phase one [P1], phase two [P2]). Patients in both phases received VenDex (oral Ven 800 mg/day + oral Dex 40 mg [20 mg for patients ≥75 years] on days 1, 8, and 15, per 21-day cycle). The primary objective of the P1 VenDex cohort was to assess safety and pharmacokinetics. Phase two further evaluated efficacy with objective response rate (ORR) and very good partial response or better. Correlative studies explored baseline BCL2 (BCL-2) and BCL2L1 (BCL-XL ) gene expression, cytogenetics, and recurrent somatic mutations in MM. Twenty and 31 patients in P1 and P2 with t(11;14) positive translocation received VenDex. P1/P2 patients had received a median of 3/5 lines of prior therapy, and 20%/87% were refractory to daratumumab. Predominant grade 3/4 hematological adverse events (AEs) with ≥10% occurrence included lymphopenia (20%/19%), neutropenia (15%/7%), thrombocytopenia (10%/10%), and anemia (5%/16%). At a median follow-up of 12.3/9.2 months, ORR was 60%/48%. The duration of response estimate at 12 months was 50%/61%, and the median time to progression was 12.4/10.8 months. In biomarker evaluable patients, response to VenDex was independent of concurrent del(17p) or gain(1q) and mutations in key oncogenic signaling pathways, including MAPK and NF-kB. VenDex demonstrated efficacy and manageable safety in heavily-pre-treated patients with t(11;14) R/R MM.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Am J Hematol. 2021. PMID: 33368455. doi:10.1002/ajh.26083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。